Research programme: DNase armored CAR T cell therapies - Xenetic Biosciences/CLS Therapeutics
Latest Information Update: 28 Jun 2026
At a glance
- Originator Xenetic Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 01 Jun 2026 Preclinical trials in Haematological malignancies in USA (Parenteral), prior to June 2026
- 01 Jun 2026 Pharmacodynamics data from a preclinical trial in Hematological malignancies released by Xenetic Biosciences